Em P Ana Alfirevic MD, PhD

Professor Pharmacology & Therapeutics

Research

Research Group Membership

Research Grants

North West Coast CLAHRC

DEPARTMENT OF HEALTH & SOCIAL CARE (UK), LCCG - LIVERPOOL CLINICAL COMMISSIONING GROUP (UK)

January 2014 - June 2021

PhD Bench fees Faten Fahad I Bin Dayel (201424089)

ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)

October 2019 - September 2022

NIHR ARC 2 national social care implementation projects

DEPARTMENT OF HEALTH & SOCIAL CARE (UK), LCCG - LIVERPOOL CLINICAL COMMISSIONING GROUP (UK)

October 2019 - March 2026

The role of transporters in the uptake of AV-101

VISTAGEN THERAPEUTICS, INC (USA)

September 2017 - February 2023

Systems pharmacology approaches to drug-induced hypersensitivity reactions

MALAYSIAN GOVERNMENT (MALAYSIA)

March 2015 - February 2018

PREDICTION-ADR: Personalisation of tREatment In Cardiovascular disease through next generation sequencing in Adverse Drug Reactions

EUROPEAN COMMISSION

September 2013 - February 2017

Genetic markers for carbamazepine-induced hypersensitivty syndrome

EPILEPSY RESEARCH INSTITUTE UK (UK)

June 2012 - November 2013

A pharmacogenomic approach to coumarin anticoagulant therapy (PACT)

EUROPEAN COMMISSION

October 2008 - March 2013

EURIPIDES - EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

EUROPEAN COMMISSION

February 2008 - January 2013

Pharmacogenetics of Methadone response

NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL (AUSTRALIA)

September 2010 - February 2013

Research Collaborations

JC Smith

External: AstraZeneca Pharmceuticals

1)The role of HSP70 gene cluster polymorphisms in carbamazepine induced hypersensitivity reactions
2) Genetic polymorphisms and tacrine induced hepatotoxicity